Powerful efficacy demonstrated with TALVEY® monotherapy1,3

Naïve to T-cell redirection therapy*

  • 73.6% ORR with Q2W dosing (95% CI, 63.0%–82.4%) (n=65/87)
  • 73% ORR with QW dosing (95% CI, 63.2%–81.4%) (n=73/100)

Exposed to T-cell redirection therapy*

  • 72% ORR with QW dosing (95% CI, 53%–86%) (n=23/32)